Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. - Wikidata - awgldk - TriplyDB

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

http://www.wikidata.org/entity/Q37640907

about

Corticosteroids for the treatment of Duchenne muscular dystrophy Assisted standing for Duchenne muscular dystrophy Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials Current and emerging treatment strategies for Duchenne muscular dystrophy Clinical utility of serum biomarkers in Duchenne muscular dystrophy The importance of genetic diagnosis for Duchenne muscular dystrophy Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview Proteomic profiling of the dystrophin-deficient mdx phenocopy of dystrophinopathy-associated cardiomyopathy Splicing therapy for neuromuscular disease Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS Bone health and associated metabolic complications in neuromuscular diseases Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using Kinect Quality improvement in neurology: muscular dystrophy quality measures Duchenne muscular dystrophy: the management of scoliosis Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture The role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymes The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy Night Activity Reduction is a Signature Physiological Biomarker for Duchenne Muscular Dystrophy Dogs.Murine and human myogenic cells identified by elevated aldehyde dehydrogenase activity: implications for muscle regeneration and repair Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review The Need for Standardized Assessment of Muscle Quality in Skeletal Muscle Function Deficit and Other Aging-Related Muscle Dysfunctions: A Symposium Report.The management of osteoporosis in children.Three-dimensional optical coherence micro-elastography of skeletal muscle tissue.Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy.The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.Chemical shift-based MRI to measure fat fractions in dystrophic skeletal muscle.Functional Neuronal Differentiation of Injury-Induced Muscle-Derived Stem Cell-Like Cells with Therapeutic Implications.Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network.Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials Les objets connectés peuvent-ils aider les patients atteints de pathologies neuromusculaires ?Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor.Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.Incidence and severity of myofiber branching with regeneration and aging.

P2860

Q24185788-7AC1CEDC-DB28-4241-981B-B6F95D2E161D Q24187775-AED1EDDB-14F1-4639-8382-8BB00F7C01A3 Q24601770-4FCD87F0-AB86-4567-8F4E-B836E2A9CE8F Q24616493-112F3FD9-1255-41B4-9FC1-7B9864045061 Q26741409-4470A526-7BD8-48A7-BEE3-AA4507BDAEF5 Q26741535-99A3B7B9-FF87-420A-934D-AE70D51C8D7E Q26751261-D2C77575-5A80-450E-BAFE-F8B135C465FC Q26769701-65406FDF-FBEC-42E0-8E63-D6517C28A296 Q26777206-06900F9D-4F97-431A-9B87-C1FB77DAFD2D Q26785627-D30D38A0-E3EC-4A67-B3D1-3ED86AE9BF65 Q26849430-B57F0BB5-C113-45EB-B13D-AE0A7898E168 Q27006945-4513B626-1286-4592-9C5A-B09B71384853 Q27009581-8D7A3F73-F133-4A75-99B4-BCD185358A6C Q27021649-91938F09-288F-408A-AE57-218B0CD980FC Q27025688-BC2895AF-5BD2-49B3-900D-527774BC5F31 Q27318308-45D1588F-7B10-45CB-B783-964A8860F607 Q27332140-913545A5-5192-4BE7-B0BD-D7893DC515C3 Q27348818-9F7A5DC6-7DFC-4934-A559-7A65F2A24E7F Q28067793-09688B34-9B05-457B-B41F-F64A41FD5CFD Q28072269-1F3F4657-FB18-453C-A5CA-9A55B46DA3B3 Q28076877-7918CED6-3FD3-4A41-BE40-48540A056C87 Q28088277-42049438-9261-4998-BDC1-9C45CE9879D9 Q28484851-DAD23FCE-1C31-464F-8A96-0C93F8350BC6 Q28596730-D3D89457-DE24-4498-BAB1-DB37F93D1799 Q28741359-1B550B7D-9FBA-460F-8242-BAD07EC2CF73 Q30000808-0E86A95F-2D0B-492D-99C7-B8865B6AAA2E Q30234649-5BDB6561-7E28-49AF-8CB6-CB9C3954AC8B Q30235428-1DEC0195-28E5-415C-8B12-E67AF0AABC1C Q30251490-815ABC0E-CE2F-40A1-8B79-EEEC83469C23 Q30426112-3D4880BD-D73F-423F-978B-C761FC947092 Q30546319-71AA9E9D-777C-46C7-8B9D-F0489A59B409 Q30557216-64EF05C1-C317-4754-A244-26BA19775332 Q30665063-0BC642FB-93A6-4FB3-819F-FA24963C941A Q30850601-5470A086-C16A-4B3F-8FEE-FECEEB51D3C6 Q30960550-6595DE28-6919-45E2-91CF-2486EB440939 Q31131975-9FA4B415-49E9-4931-B55F-91D4BE5D17BF Q33451552-C2F6F3F8-C0E0-4E83-9691-AEF31DEC0D97 Q33570741-45E7B16E-57BC-416B-B69D-5614D6E3D2DB Q33635762-83FD6C91-ECC1-448F-A0C1-F9D9A5436E82 Q33646492-D2EC4189-D47B-4953-863C-2C3DB59203FD

P2860

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

http://www.wikidata.org/entity/Q37640907

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Diagnosis and management of Du ...... l and psychosocial management.

@en

Diagnosis and management of Du ...... l and psychosocial management.

@nl

type

label

Diagnosis and management of Du ...... l and psychosocial management.

@en

Diagnosis and management of Du ...... l and psychosocial management.

@nl

prefLabel

Diagnosis and management of Du ...... l and psychosocial management.

@en

Diagnosis and management of Du ...... l and psychosocial management.

@nl

P1433

Q37640907-E7DCE2D8-D7C1-4884-A757-66F85D770E12

P1476

Q37640907-FECDAF48-A67D-425F-8F7C-71D1E37C213B

P2093

Q37640907-246F2DB9-E1E9-40F0-BA39-C38B7AE0281F

Q37640907-2AE6B6D5-B93E-489C-8E42-C5FA9FE92850

Q37640907-489EF392-BDB5-4F86-8AEB-2F5F37CAC8F7

Q37640907-51495B4B-A535-48F4-AD81-DB52E8B7F054

Q37640907-52E8BA28-86C8-448A-A851-7D0E53542A9E

Q37640907-7D9A9268-E2E0-41B8-ACE6-3E8368524E12

Q37640907-80E54FE6-E6C7-44A1-B6E2-7CF35B9F7699

Q37640907-89479E01-CA5D-4AD7-972D-41799AFAA00C

Q37640907-8EDDBC63-C98E-4113-89D5-4C105F23289F

Q37640907-D8932E07-89A9-4BDC-944B-E1F57D947F74

P304

Q37640907-7311649F-6EBC-4B0D-B513-296B29445894

P31

Q37640907-C122238F-49C4-4A8B-818E-51CB2183210C

P356

Q37640907-E64D011F-6C29-4F2B-9DE4-8B398802CBAA

P433

Q37640907-5CC1D3E7-3C41-455C-85A9-DD614E923972

P478

Q37640907-64FD31E3-0FAE-4303-B5F1-2586D1FD1D08

P50

Q37640907-3985B1E7-FD51-4A9A-929F-2E742A927396

Q37640907-527A0EDC-0D6C-4566-8313-111B2173DC8E

Q37640907-A14EE351-387C-4C6B-BC28-4CC2A5C19B6A

P577

Q37640907-E489EE85-D59C-4516-9CD3-82CADF548CDA

P698

Q37640907-5984F48B-8621-471C-B5C0-FB1B7C7F981F

P921

Q37640907-47598AF5-4F6F-4E26-9F64-F174AAB4503E

Q37640907-c7250326-8dec-4cc7-aecd-85813b8c76e2

P356

S1474-4422(09)70271-6

P1433

Lancet Neurology

P1476

Diagnosis and management of Du ...... l and psychosocial management.

@en

P2093

Ajay Kaul

http://www.w3.org/2001/XMLSchema#string

Carolyn Constantin

http://www.w3.org/2001/XMLSchema#string

DMD Care Considerations Working Group

http://www.w3.org/2001/XMLSchema#string

Frederic Shapiro

http://www.w3.org/2001/XMLSchema#string

James Poysky

http://www.w3.org/2001/XMLSchema#string

Jean Tomezsko

http://www.w3.org/2001/XMLSchema#string

Katharine Bushby

http://www.w3.org/2001/XMLSchema#string

Kathi Kinnett

http://www.w3.org/2001/XMLSchema#string

Linda Cripe

http://www.w3.org/2001/XMLSchema#string

Paula R Clemens

http://www.w3.org/2001/XMLSchema#string

P304

77-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(09)70271-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Craig M. McDonald

David J Birnkrant

P577

2009-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19945913

http://www.w3.org/2001/XMLSchema#string

P921